The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerBroad targeting of angiogenesis for cancer prevention and therapyIncreased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-BChronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in miceCombined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.The thrombospondins.The interconnectedness of cancer cell signaling.Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model.Early life exposure to undernutrition induces ER stress, apoptosis, and reduced vascularization in ovaries of adult rat offspring.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationThrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.Targeting the Fas/FasL signaling pathway in cancer therapy.Antiangiogenic and anticancer molecules in cartilage.Non-hormonal targets underlying endometriosis: A focus on molecular mechanisms.An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationCo-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome.SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.Hydrophobic benzyl amines as supports for liquid-phase C-terminal amidated peptide synthesis: application to the preparation of ABT-510.
P2860
Q24628746-AFFAA01B-C120-4B3B-916A-DAF39762B544Q27002903-2C7BB99C-EFC5-40E2-9092-0DF559F61375Q33922852-B4BC3C97-2A68-43F5-A3FA-D05A04306C3AQ34584625-FCA91D74-BE49-4544-9025-98C68BA30005Q35039333-1FC546FE-C8C3-45A3-9A7E-C07125B6EA90Q35230013-E4382026-9299-4FDE-ABDB-E8EAAD1C7B1DQ35669733-D37E7712-6F01-4598-8D79-C1104DE06E06Q35902676-48C5D6AF-57EE-49AA-A1D4-398FC38C5A8EQ36113958-30517D90-3852-46B5-B5CD-064AB2ED44E5Q36237770-05110DE0-1B68-4374-A8B3-B07520E84343Q36277278-72853433-BA70-4A77-B1B0-34B7FC9F9DD4Q36578825-E934EB58-3FEB-4F43-A985-F31D10CB5BE6Q36586178-76B57130-4994-4EC3-9629-E3E7380D62D9Q37963916-AFD30985-37D2-4C46-94B4-0647C4355AA0Q37975245-EC4BD2AC-C94B-4C66-B936-0ECDEDEC0F69Q38007565-E50E12FF-9988-487E-991B-B24A0DE162F4Q38486433-D65706A3-6D7F-4E21-A337-D3A8F6988401Q39325959-1D714DCE-D58F-4261-9BBB-4EB2499AC5BCQ39524316-54A62E92-35C3-4613-AFC7-F42ADDB70B8BQ41879186-964E9A0A-81EF-4B7D-9A95-CA785759705BQ42379504-4BA2524D-6946-4626-A776-A9E4E7D6CCFFQ47106590-AA9CB43E-5AB6-4AC6-89FD-54FFE4F2D9FFQ47717341-88710729-4FE0-4F92-8C6E-77E7F97F4BDCQ51838553-5B7463F4-38F9-488D-BFEC-561A6EBE4F78
P2860
The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@ast
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@en
type
label
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@ast
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@en
prefLabel
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@ast
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@en
P2093
P2860
P356
P1433
P1476
The thrombospondin-1 mimetic A ...... of epithelial ovarian cancer.
@en
P2093
Jack Henkin
James Greenaway
Jim Petrik
Nicole E Campbell
Roger A Moorehead
P2860
P304
P356
10.1593/NEO.91880
P577
2010-03-01T00:00:00Z